Alma, the Energy‑Based Devices brand of Sisram Medical, showcased at IMCAS World Congress 2026 in Paris a technology-driven vision for Intelligent Aesthetics, focusing on scar management, rejuvenation, and tattoo removal.

New clinical data and case studies highlighted multi-technology laser platforms that enable advanced rejuvenation and complex tattoo removal using multiple wavelengths on a single platform.

Demonstrations at IMCAS reinforced Alma’s leadership in intelligent energy‑based aesthetic solutions through evidence of multi-technology platforms and the use of multiple wavelengths for complex tattoo removal.

Eyal Ben David, CEO of Sisram and Alma, framed IMCAS as a key scientific platform and stressed a move toward precision diagnostics, personalized treatment planning, and integrated care pathways to improve outcomes.

Executive takeaway: Alma underscored evidence‑based, personalized, and integrated care pathways to boost patient outcomes and sustained engagement in aesthetic practices, signaling Sisram’s commitment to Intelligent Aesthetics.

Sisram Medical is a global leader in aesthetic solutions with over 25 years of Energy‑Based Devices experience, serving more than 110 countries, majority‑owned by Fosun Pharma and listed on the Hong Kong Stock Exchange since 2017.

Alma demonstrated the Hybrid platform’s approach to managing keloid scars in conjunction with surgery and trans‑epidermal delivery of steroids, plus acne and acne‑scar management across the clinical spectrum.

Key applications featured included the Alma Hybrid platform for managing keloid scars with surgical synergy and trans‑epidermal steroid delivery, alongside acne and acne‑scar management.

Live demonstrations showcased Harmony Bio‑Boost for collagen‑stimulating rejuvenation and Alma IQ, a skin‑analysis platform that enables personalized treatment planning from the first patient interaction.

Lior Dayan, Chairman of Sisram, attended the IMCAS Economic Forum La Tribune 2026 to discuss how intelligent technologies and clinical insight are shaping the future of medical aesthetics.

The press materials position Alma as advancing evidence‑driven aesthetic practice through technology and clinical data.